Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

HARMONi and HARMONi-3 Enrollment Continues


Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...

Related Keywords

Miami ,Florida ,United States ,Japan ,Canada ,Spain ,Cleveland Clinic ,Sweden ,California ,South Korea ,Germany ,United Kingdom ,China ,Italy ,Menlo Park ,France ,Stanford ,Leicestershire ,Australia ,Stockholm ,Han ,Chinese ,American ,Mostafa Ronaghi ,Drug Administration ,Royal Institute Of Technology ,Nasdaq ,Stanford Genome Technology Center ,Akeso Inc ,Illumina Inc ,International Agency For Research On Cancer ,Us National Cancer Institute ,Development Rd Expenses ,American Cancer Society ,Development Expense ,World Health Organization ,National Institute Of Health ,Exchange Commission ,Summit Therapeutics Inc ,Japan National Cancer Registry ,Development Expenses ,Md Anderson Cancer Center ,Summit Therapeutics ,License Agreement ,Executive Board Member ,Chief Technology Officer ,Principal Investigator ,Royal Institute ,Cash Equivalents ,Restricted Cash ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended March ,Consolidated Balance Sheet ,Consolidated Statement ,Cash Flows ,Process Research ,Loss Per Common ,Loss Per Basic ,Diluted Common Share ,Per Basic ,Diluted Common ,Administrative Expenses ,Critical Terms Contained ,Death Ligand ,Proportion Score ,Response Assessment ,Vascular Endothelial Growth Factor ,Cancer Society ,International Agency ,Japan National Cancer ,Cancer Epidemiology ,Positive Lung Cancer ,Endothelial Growth Factor ,Its Receptor ,Crucial Target ,Cancer Institute ,National Institute ,Accessed April ,Current Researches ,Markets ,